To explore the potential clinical factors associated with outcome of ICI plus chemotherapy, we firstly compared the baseline characteristics between CB and NB groups, and found no difference in all common characteristics including age, sex, smoking history, pathology, distant metastasis, gene mutation subtype, T790M mutation, PD-L1 expression, and immunotherapy treatment line. The gene discussed is CD274; the disease is neuroblastoma.